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Objective: Studies of infrainguinal lower extremity bypass for critical limb ischemia (CLI) have traditionally emphasized
outcomes of patency, limb salvage, and death. Because functional outcomes are equally important, our objectives were to
describe the proportion of CLI patients who did not achieve symptomatic improvement 1 year after bypass, despite
having patent grafts, and identify preoperative factors associated with this outcome.
Methods: The prospectively collected Vascular Study Group of Northern New England database was used to identify all
patients with elective infrainguinal lower extremity bypass for CLI (2003 to 2007) for whom long-term follow-up data
were available. The primary composite study end point was clinical failure at 1 year after bypass, defined as amputation
or persistent or worsened ischemic symptoms (rest pain or tissue loss), despite a patent graft. Variables identified on
univariate screening (inclusion threshold, P < .20) were included in a multivariable logistic regression model to identify
independent predictors.
Results: Long-term follow-up data were available for 1012 patients who underwent infrainguinal bypasses for CLI, of
which 788 (78%) remained patent at 1 year. Of these, 79 (10%) met criteria for the composite end point of clinical failure:
21 (2.7%) for major amputations and 58 (7.4%) for persistent rest pain or tissue loss. In multivariable analysis, significant
predictors of clinical failure included dialysis dependence (odds ratio [OR], 3.74; 95% confidence interval [CI],
1.84-7.62; P < .001) and preoperative inability to ambulate independently (OR, 2.17; 95% CI, 1.26-3.73; P  .005). A
history of coronary artery bypass graft or percutaneous coronary intervention was protective (OR, 0.52; 95% CI,
0.29-0.93; P  .03).
Conclusions: After infrainguinal lower extremity bypass for CLI, 10% of patients with a patent graft did not achieve
clinical improvement at 1 year. Preoperative identification of this specific patient subgroup remains challenging. To
improve surgical decision making and the overall care of CLI patients, further emphasis needs to be placed on functional
outcomes in addition to traditional surgical end points. ( J Vasc Surg 2010;51:1419-24.)Themanagement of patients with critical limb ischemia
(CLI) remains complex, with several factors contributing
to the treatment decision-making process. Traditional
study end points for these patients have included graft
patency,1,2 limb salvage,3,4 or death.5,6 More recently,
however, alternative end points have emerged that include
amputation-free survival,7-9 major adverse cardiovascular
events,9 target limb revascularization,10 quality of life,11
and functional outcomes such as the ability to ambulate or
to live independently after surgery.6,11,12 Although these
findings, interpreted in aggregate, do suggest an associa-
tion between graft patency and quality of life, most clini-
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equate with symptom resolution and functional improve-
ment.
The proportion of patients that does not experience
clinical improvement at 1 year postoperatively, despite in-
frainguinal graft patency, has not been well delineated.
Therefore, the objective of the current investigation was to
use the prospectively collected Vascular Study Group of
Northern New England (VSGNNE) database to address
this question. In addition, we sought to identify preopera-
tive factors associated with persistent ischemic symptoms or
ipsilateral amputation, despite graft patency, to improve
preoperative patient counseling.
METHODS
Cohort assembly. The VSGNNE is a regional coop-
erative quality improvement initiative that was developed in
2002 to prospectively evaluate outcomes in patients under-
going vascular surgery. Eleven teaching and nonteaching
hospitals with 59 vascular surgeons (community and aca-
demic) currently participate in this program by reporting
data into the registry. All data are self-reported and sent to
a central data repository where they are aggregated and
reviewed. Research analysts are blinded to patient, surgeon,
and hospital identity.
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perioperative data sheet containing preoperative, intraop-
erative, and postoperative data is completed and submitted
to the VSGNNE. The VSGNNE does not mandate a
specific protocol for graft surveillance or medical or wound
therapy after lower extremity bypass. These specific man-
agement decisions are left to the discretion of the operating
surgeon.
The study design for the VSGNNE registry emphasizes
the importance of collecting follow-up data at 1 year for all
patients with procedures entered into the registry. To facil-
itate compliance with this requirement, the central site
sends an electronically automated follow-up form for each
operation to each surgeon in advance of the expected
1-year office visit. Accordingly, at the approximate 1-year
follow-up, this data sheet is completed and submitted to
the VSGNNE (acceptable window for the current analysis
was 6 to 18 months). Data pertaining to ambulation status,
symptom status, patency, ankle-brachial index, bypass graft
revisions, or amputations are recorded on this form. Since
the inception of the study, a claims-based audit system has
been used that has demonstrated 99% accuracy in capturing
consecutive operations performed at each center. Details
relating to the VSGNNE study design have been published
previously13 and are available at the VSGNNE Web site
(www.vsgnne.org).
For the purpose of this study, the VSGNNE database
was queried for patients undergoing elective and urgent
infrainguinal lower extremity bypass (iLEB) performed be-
tween January 1, 2003, and December 31, 2007, for an
indication of CLI (defined as tissue loss or ischemic rest
pain). To assess outcomes at 1 year, patients were excluded
if they did not have a completed 1-year follow-up form that
included all data pertaining to symptom status and patency,
resulting in 445 of the 1457 patients being excluded (Fig
1). All infrainguinal bypass configurations were included
for analysis, regardless of the specific inflow site, outflow
Fig 1. Flowchart shows cohort selection for primary analysis of
clinical failure, defined as persistent rest pain, tissue loss, or ipsilat-
eral major amputation at 1 year, despite a patent graft.CLI,Critical
limb ischemia; iLEB, infrainguinal lower extremity bypass.site, or conduit.Covariates examined. Patient information for 70
clinical and demographic variables (available at www.vsgnne.
org) was collected. Comorbidities examined included cor-
onary artery disease (history of myocardial infarction or
angina), chronic obstructive pulmonary disease (COPD,
medication-dependent or home oxygen-dependent),
congestive heart failure (by history), diabetes mellitus (in-
sulin-dependent or controlled by oral medication or diet),
hypertension (history of hypertension or blood pressure
140/90 mm Hg on the preoperative evaluation), and
history of tobacco use (never, 1 year prior, or current).
Renal disease was categorized in three strata: normal (se-
rum creatinine 1.8 mg/dL), renal insufficiency (serum
creatinine 1.8 mg/dL), and dialysis-dependent.
Variables related to surgical history included previous
coronary artery bypass graft (CABG) or percutaneous cor-
onary intervention (PCI), as well as previous carotid, aortic,
peripheral bypass or stent, and major extremity amputa-
tion. Medication variables included preoperative use of
antiplatelet agents, statins, or -blockers. Functional vari-
ables included preoperative living status (home or nursing
home) and ambulation status (independent, with assis-
tance, wheelchair-bound, and bed-bound).
Also evaluated were procedural details, such as ur-
gency, bypass conduit, and bypass target vessel. Bypass
conduit was considered a preoperatively available variable,
based on an assumption that most patients undergoing
bypass surgery receive vein mapping, allowing for a preop-
erative determination of conduit availability. Long-term
follow-up data included vital status, patency of the graft
(whether primary or secondary by duplex graft surveillance
scan), amputation status, and symptoms (asymptomatic,
claudication, rest pain, or tissue loss). Vital status was
confirmed for all patients using follow-up visit notes and a
current version of the Social Security Death Index.
Primary end point. Clinical failure, which was the
primary end point, was defined as rest pain, tissue loss, or
ipsilateral amputation (major amputation is defined as
above- or below-knee [loss of foot] amputation) at long-
term follow-up, despite a patent graft. The study excluded
four patients who did not undergo amputation but were
missing information on their symptoms at follow-up.
Statistical analysis. Baseline characteristics were com-
pared between groups using Pearson 2 analysis for cate-
goric variables and the t test for continuous variables. Those
variables with a value of P  .2 were entered into a logistic
regression model for the primary outcome of clinical fail-
ure. Significance was accepted at the P  .05 level. All
analyses were conducted using SAS 9.1 software (SAS
Institute, Cary, NC).
RESULTS
Cohort characteristics. Between 2003 and 2007,
1457 patients underwent elective or urgent iLEB for CLI at
11 participating centers. The perioperative death rate, de-
fined as 30-day mortality, was 2.2%. After excluding 445
patients who did not specifically have patency or symptom
status information at the 1-year follow-up, 1012 patients
All categoric values are presented as number (%); the continuous variable
(age) is given as mean  standard deviation.
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excluded, 165 had died before the 1-year follow-up visit,
71 had incomplete symptom or patency status information,
and 209 were lost to follow-up (Fig 1). Of the remaining
1012 patients (69%), 788 (78%) had patent grafts and 224
(22%) had occluded grafts at 1 year after bypass (Fig 1).
Patency at long-term follow-up was judged by duplex
examination in 419 patients (55.9%), a palpable graft/
distal pulse in 277 (37.0%), and by ankle-brachial index
increase .15 in 53 (7.1%). The method for judging graft
patency was not reported for the remaining 39 patients
(4.9%). Mean length of follow-up was 346.9 days (standard
deviation, 6.6 days).
Among patients with a patent graft at follow-up, 68%
were men, 99%were white, and 82%were current or former
smokers. A history of coronary artery disease (CAD) was
present in 40%, but only 2% had unstable angina or had
sustained a myocardial infarction 6 months before sur-
gery. The prevalence of diabetes was 59%, of which 31%
were insulin-dependent, 22% were treated with oral medi-
cations, and 6% were managed with diet alone. Renal
function was normal (creatinine 1.8 mg/dL) in 85%,
abnormal but without dialysis (creatinine 1.8 mg/dL) in
9%, and sufficiently poor to necessitate permanent dialysis
in 6%. Of the 30% of patients with COPD, 2% required
home oxygen therapy. Operations were elective in 78% of
patients.
Details of the analysis cohort, stratified according to the
end point of clinical failure, are presented in Table I. Salient
differences seen in those who experienced clinical failure
include a greater proportion of patients who were dialysis-
dependent (17.7% vs 5.0%, P  .0001), residing in a
nursing home (7.6% vs 3.9%, P  .13), had a history of
contralateral major amputation (7.6% vs 4.2%, P  .17),
were not ambulating independently preoperatively (45.6%
vs 24.7%, P  .0001), and underwent nonelective opera-
tion (34% vs 20%, P  .005).
At the time of follow-up, 121 major ipsilateral ampu-
tations had been performed (Table II). Amputation oc-
curred far more frequently among patients with an oc-
cluded graft (44.6% of 224 limbs) than in patients with
patent grafts (2.7% of 788 limbs). Of an additional 58
Table II. Patient outcomes at 1-year follow-up after
infrainguinal lower extremity bypass for critical limb
ischemiaa
Symptom
Bypass graft status, No. (%)
P value
Patent
(n  788)
Occluded
(n  224)
Asymptomatic 634 (80.5) 43 (19.2) .0001
Claudication 75 (9.5) 38 (17.0)
Rest pain 16 (2.0) 14 (6.3)
Tissue loss 42 (5.3) 29 (13.0)
Ipsilateral amputation 21 (2.7) 100 (44.6)
aUnivariate comparison included.Table I. Patient characteristics in 788 patients with a
patent bypass graft at 1 yeara
Covariatesb
Improved
(n  709)
Unimproved
(n  79) P value
Demographics
Age, y 69.5  11.1 68.0  11.1 .25
Female gender 230 (32.4) 23 (29.1) .55
Race .84
White 698 (98.5) 78 (98.7)
Nonwhite 11 (1.5) 1 (1.3)
Preoperative factors
Smoking status .90
Never 123 (17.4) 15 (19.0)
Prior history 299 (42.2) 34 (43.0)
Current 286 (40.4) 30 (38.0)
Coronary artery disease 285 (40.2) 29 (36.7) .55
History of CABG or PCI 236 (33.3) 18 (22.8) .06
Congestive heart failure 131 (18.5) 15 (19.0) .91
Hypertension 613 (86.5) 72 (91.1) .24
Insulin-dependent
diabetes 210 (29.6) 36 (45.6) .004
COPD 205 (28.9) 29 (36.7) .15
Renal function .0001
Creatinine 1.8
mg/dL 606 (86.7) 55 (69.6)
Creatinine 1.8
mg/dL 58 (8.3) 10 (12.7)
Dialysis-dependent
(any creatinine) 35 (5.0) 14 (17.7)
Previous
Arterial bypass (any) 198 (27.9) 18 (22.8) .33
PTA or stent
(ipsilateral) 34 (4.8) 7 (8.9) .12
Major amputation
(contralateral) 30 (4.2) 6 (7.6) .17
Living .13
Home 680 (96.1) 73 (92.4)
Nursing home 28 (3.9) 6 (7.6)
Ambulation status .0001
Independent 534 (75.3) 43 (54.4)
With assistance 135 (19.0) 29 (36.7)
Wheelchair-bound 34 (4.8) 4 (5.1)
Bed-bound 6 (0.9) 3 (3.8)
Technical factors
Urgency .005
Elective 565 (79.7) 52 (65.8)
Urgent 144 (20.3) 27 (34.2)
Prosthetic bypass
conduit 168 (23.7) 18 (22.8) .60
Single-segment GSV 477 (67.4) 53 (67.1) .96
Recipient vessel .58
Above-knee popliteal 162 (22.9) 14 (17.7)
Below-knee popliteal 223 (31.5) 27 (34.2)
Tibial/other 324 (45.7) 38 (48.1)
Medications
Aspirin 489 (69.0) 52 (65.8) .57
Clopidogrel 72 (10.2) 6 (7.6) .47
Statin 389 (54.9) 46 (58.2) .57
-blockers 599 (84.5) 65 (82.3) .85
CABG,Coronary artery bypass graft;COPD, chronic obstructive pulmonary
disease; GSV, great saphenous vein; PCI, percutaneous coronary interven-
tion; PTA, percutaneous transluminal angioplasty.
aUnivariate comparison between those whose symptoms persisted or re-
quired a major amputation and those who demonstrated improvement at
1-year follow-up.
bpatients (7.4%) with patent bypass grafts, 16 reported per-
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follow-up. Therefore, 79 patients (10%) reached the com-
posite end point of clinical failure, despite having docu-
mented patent bypass grafts.
Analysis by indication. When outcomes were ana-
lyzed according to indication for surgery (rest pain or tissue
loss), most patients in both groups were asymptomatic at
long-term follow up (Fig 2). Among the 282 patients with
rest pain preoperatively, 82.6% were asymptomatic, 12.8%
reported claudication, 2.1% still had rest pain, 1.8% had
progressed to tissue loss, and 0.7% had undergone major
amputation. The distribution of outcomes was less favor-
able among the 506 patients with tissue loss preoperatively:
79.3% were asymptomatic, 7.7% reported claudication,
2.0% had rest pain, 7.3% still had tissue loss, and 3.8% had
undergone major amputation.
Predictors of clinical failure. Nine covariates demon-
strated values of P .20 on univariate analysis (Table I) and
were entered into the multivariable model. On multivariable
analysis, two independent predictors of clinical nonimprove-
ment were identified (Table III). Dialysis-dependence was
associated with a 3.7-fold increase in the odds of clinical
failure compared with patients with normal renal function
(odds ratio [OR], 3.74; 95% confidence interval [CI],
1.84-7.62). Preoperative ambulation with assistance was
also predictive of clinical failure compared with indepen-
dent ambulation status (OR, 2.17; 95% CI, 1.26-3.73).
Insulin-dependent diabetes demonstrated a nonstatistically
significant trend toward increased odds of clinical failure
(OR, 1.65; 95% CI, 0.99-2.75, P  .054). History of
CABG or PCI was protective against clinical failure (OR,
0.52; 95% CI, 0.29-0.93).
DISCUSSION
Among patients with CLI, 10% reported symptoms
that were not improved at 1 year after lower extremity
bypass, despite having patent grafts. These results are con-
Fig 2. Transition of health states are shown at the 1-year follow-up
according to indication for lower extremity bypass.sistent with other reports of the incidence of unsatisfactoryoutcomes after iLEB despite functioning grafts. Dietzek et
al14 highlighted this problem in 1990 with a retrospective
review of 987 patients, 7.6% of whom experienced limb loss
despite patent infrainguinal bypass. A second series demon-
strated that 9% of extremities with patent grafts required
amputation.15
This analysis also sought to identify risk factors for
clinical failure that can be identified preoperatively to opti-
mize clinical decision making for patients with CLI. We
identified two primary independent preoperative predic-
tors: dialysis-dependence, which conferred a 3.7-fold in-
creased risk, and ambulation with assistance, which more
than doubled the risk. Of note, although ambulation with
assistance preoperatively was a risk factor for clinical failure
compared with independent ambulation, wheelchair-
bound and bed-bound status did not reach statistical sig-
nificance, possibly reflecting the small numbers of patients
in these groups. Alternatively, this may reflect that patients
with more significant functional impairments have more
assistance with wound care and are less likely to repeatedly
traumatize their extremities with impaired ambulation.
An exploratory analysis of the cohort, after the exclu-
sion of patients whowere wheelchair-bound or bed-bound,
yielded a univariate screen with largely similar results.When
entered into the logistic regression model, a similar pattern
emerged in terms of significant predictors, with dialysis-
dependence conferring a 4.7-fold increase in odds of clini-
cal failure and ambulation with assistance carrying a 2-fold
increase in odds of clinical failure. A similar magnitude of
effect (OR, 1.8) was also seen for insulin-dependent diabe-
tes, which reached statistical significance. A history of
Table III. Multivariable model for the preoperative
predictors of persistent rest pain, tissue loss, or
amputation despite graft patency one year after
infrainguinal lower extremity bypass
Covariate
Adjusted OR
(95% CI) P value
History of CABG or PCI 0.52 (0.29-0.93) .027
Insulin-dependent diabetes 1.65 (0.99-2.75) .054
COPD 1.23 (0.74-2.04) .43
Renal function
Creatinine 1.8 mg/dL Ref . . .
Creatinine 1.8 mg/dL 1.85 (0.85-4.01) .12
Dialysis-dependent (any creatinine) 3.74 (1.84-7.62) .0003
History of ipsilateral PTA or stent 1.82 (0.74-4.47) .19
History of contralateral major
amputation 1.42 (0.52-3.85) .49
Non-nursing home resident 0.87 (0.30-2.52) .80
Preoperative ambulation status
Independent Ref . . .
With assistance 2.17 (1.26-3.73) .005
Wheelchair-bound 1.05 (0.31-3.63) .93
Bed-bound 3.47 (0.76-15.98) .11
Urgent procedure (ref  elective) 1.58 (0.93-2.69) .094
CABG, coronary artery bypass graft;CI, confidence interval;COPD, chronic
obstructive pulmonary disease;OR, odds ratio; PCI, percutaneous coronary
intervention; PTA, percutaneous transluminal angioplasty; Ref, referent.CABG or PCI was not significant in this model.
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study demonstrated was protective against clinical failure
was a history of CABG or PCI. This effect persisted on
multivariable analysis, which controlled for potential rele-
vant measured confounders. The mechanism for this risk
reduction is not clear. It may be that this represents up-
front selection bias. A history of coronary intervention may
describe a patient who has survived a major operation and
thus is healthier than a patient who has not undergone
intervention. Also, this variable may indicate a benefit asso-
ciated with a comprehensive cardiac rehabilitation pro-
gram, possibly including better fitness or more attentive
wound care, or both. Finally, there may be some other
mechanism by which history of coronary intervention pre-
serves functional status or improves wound healing, the
precise nature of which cannot be ascertained from these
data alone.
The predictors of clinical failure identified in this anal-
ysis (dialysis-dependence and ambulation with assistance)
differ somewhat from those identified in other reports of
clinical failure in the setting of a patent bypass graft, which
have included diabetes, extensive pedal necrosis, and ad-
vanced infection,14 as well as black race and distal anasto-
mosis to the anterior tibial or dorsalis pedis.15 The identi-
fication of dialysis-dependence as a risk factor for clinical
failure, however, is consistent with a wide body of litera-
ture.
As in our study, Carsten et al15 identified chronic renal
failure as an independent predictor of amputation despite
graft patency. In another review that focused specifically on
end-stage renal disease (ESRD), 59% of patients who un-
derwent infrainguinal bypass for CLI eventually required a
major amputation despite having a patent bypass graft.16
Finally, a meta-analysis of 28 reports of iLEB outcomes in
patients with ESRD found an overall 10% incidence of
amputation despite graft patency,17 equal to that observed
in our analysis.
These marginal outcomes in patients with ESRD have
prompted some authors to suggest that iLEB should not be
offered to patients with ESRDwho have extensive infection
or tissue loss, because high rates of death and early ampu-
tation may outweigh the potential benefits associated with
surgical revascularization.17 Others, however, have sug-
gested a more cautious interpretation, concluding that
careful risk stratification is imperative, but broad sweeping
guidelines are not appropriate.8,9,16,18
We agree that predictors of clinical failure, identified in
our study or others, cannot be interpreted in isolation and
must be considered in the context of various patient-related
and provider-related factors. Rather than offer a definitive
set of criteria by which patients should be managed, our
findings highlight the need for continued research into
nontraditional end points that may have profound effects
on patients undergoing treatment for CLI. With a 10%
incidence of clinical failure, preoperative counseling should
not be limited only to a discussion regarding the risks of
graft occlusion, morbidity, andmortality, but patients mustalso understand that graft patency may not guarantee
symptomatic improvement.
It is important to recognize that this analysis is limited
only to patients who underwent open iLEB. Many authors
have advocated that endovascular techniques may be the
treatment of choice in high-risk surgical patients owing to
the lower associated morbidity, improved limb salvage, and
decreased lengths of stay.19-21 However, the need for ma-
jor amputation has also been demonstrated to occur despite
patent endovascularly treated arterial segments.
Khan et al22 recently reported 236 limbs treated with
endovascular therapies for CLI. These authors noted am-
putation, despite a patent endovascularly treated arterial
segment, was the most common means of limb loss, and
80% of amputations occurred in patients with a patent
endovascularly treated arterial segment.22 Although pre-
dictors of limb salvage failure in this cohort with diabetes,
gangrene, and infrapopliteal interventions were similar to
those reported with open iLEB, the authors note that
because all three significant predictors of limb loss were
present in 61% of the endovascularly treated patients who
did achieve limb salvage, these risk factors may have limited
predictive utility. This again highlights our current deficit
in useful information for risk stratification for clinical failure
in patients undergoing endovascular as well those under-
going open revascularization.
There are two primary limitations inherent to this study
design. First, although all of the data analyzed in this study
were prospectively collected, they were reviewed retrospec-
tively. As a result, in the design of the present study, we
were limited to those variables that were routinely collected
by the VSGNNE. Among the notable covariates not avail-
able for analysis were the degree and extent of ulceration or
soft tissue infection, the quality of the ipsilateral runoff
vessels, and the time interval between symptom onset and
the date of surgery. Furthermore, the diagnosis of rest pain
at follow-up was self-reported and not corroborated with a
validated instrument or physiologic parameters.
Second, the analysis excluded a considerable number of
patients who did not have follow-up information. It is
possible that the patients without complete long-term
follow-up differed from those with follow-up data, thereby
introducing selection bias. Univariate comparison of the
variables entered into the logistic regressionmodel revealed
that the 445 patients excluded from the primary analysis
were significantly more likely to have had urgent opera-
tions, impaired renal function, and were less likely to am-
bulate independently and to live independently at baseline.
The other five covariates were not significantly different
between the two groups. It is also important to recognize
that these analyses were conditional on both surviving to
long-term follow-up and having a patent graft; other stud-
ies7-9 that have addressed risk factors for mortality and loss
of graft patency must also be considered in preoperative
patient counseling.
Nonetheless, our study has several notable strengths.
First, we describe the frequency of a clinically relevant
outcome. We made a deliberate decision in this study to
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amputation. We believe that the end point of clinical fail-
ure, which not only includes amputation but also persistent
or worsening symptoms (ie, rest pain or tissue loss), is a
clinically relevant condition that negates the benefits of a
patent bypass graft.
Second, we describe three preoperatively identifiable
patient factors associated with clinical failure. We also high-
light the difficulty of capturing all clinically relevant patient
characteristics in statistical models like ours. Ultimately, an
improved understanding of functional outcomes will help
refine clinical decision making and further improve patient
and physician expectations for those considering bypass
surgery. Just as traditional end points such as patency, limb
salvage, and mortality play a large role in the determination
of the optimal treatment for a patient with CLI, function
and symptom-based outcomes are of significant impor-
tance and therefore warrant further study.
CONCLUSIONS
Ten percent of patients with patent bypass grafts do not
achieve clinical improvement at 1 year after lower extremity
bypass surgery for CLI. Patients who are dialysis-dependent
(OR, 3.7) or cannot ambulate independently (OR, 2.2) are
at a markedly increased risk for this outcome. Further study
is necessary to improve preoperative risk stratification for
functional outcomes, such as clinical failure, in order to
improve the overall care of patients with CLI.
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